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Combinatorial synthesis and
screening of cancer cell-specific
nanomedicines targeted via phage
fusion proteins
James W. Gillespie, Amanda L. Gross, Anatoliy T. Puzyrev, Deepa Bedi and
Valery A. Petrenko*
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Active tumor targeting of nanomedicines has recently shown significant improvements
in the therapeutic activity of currently existing drug delivery systems, such as liposomal
doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have shown that isolated pVIII major
coat proteins of the fd-tet filamentous phage vector, containing cancer cell-specific
peptide fusions at their N-terminus, can be used as active targeting ligands in a liposomal
doxorubicin delivery system in vitro and in vivo. Here, we show a novel major coat
protein isolation procedure in 2-propanol that allows spontaneous incorporation of the
hydrophobic protein core into preformed liposomal doxorubicin with minimal damage
or drug loss while still retaining the targeting ligand exposed for cell-specific targeting.
Using a panel of 12 structurally unique ligands with specificity toward breast, lung, and/or
pancreatic cancer, we showed the feasibility of pVIII major coat proteins to significantly
increase the throughput of targeting ligand screening in a common nanomedicine core.
Phage protein-modified Lipodox samples showed an average doxorubicin recovery of
82.8% across all samples with 100% of protein incorporation in the correct orientation
(N-terminus exposed). Following cytotoxicity screening in a doxorubicin-sensitive breast
cancer line (MCF-7), three major groups of ligands were identified. Ligands showing
the most improved cytotoxicity included: DMPGTVLP, ANGRPSMT, VNGRAEAP, and
ANDVYLD showing a 25-fold improvement (p < 0.05) in toxicity. Similarly DGQYLGSQ,
ETYNQPYL, and GSSEQLYL ligands with specificity toward a doxorubicin-insensitive
pancreatic cancer line (PANC-1) showed significant increases in toxicity (2-fold; p <
0.05). Thus, we demonstrated proof-of-concept that pVIII major coat proteins can be
screened in significantly higher throughput to identify novel ligands displaying improved
therapeutic activity in a desired cancer phenotype.
Keywords: phage display, targeted nanomedicines, breast cancer, pancreatic cancer, liposomal drug delivery,
doxorubicin
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Introduction
Cancer remains the second leading cause of death in the United
States across all age groups for both genders and continues
to produce a significant burden on the healthcare system for
improved patient outcomes with an improved quality of life in
cancer survivors (Siegel et al., 2015). Treatment options include
surgery, chemotherapy, radiation therapy or a combination of the
three and are dependent on the tumor stage at initial diagnosis
and the overall health/age of the patient. For example, breast
cancer is commonly treated with surgery and radiation therapy
(60%) in early stages (I or II) with the addition of chemotherapy
in some cases (39%). However, in later stages (III or IV),
chemotherapy is used significantlymore often (74%) in a patient’s
treatment strategy (DeSantis et al., 2014). Tumor management
with chemotherapy has shown to prevent tumor recurrence and
prolong a patient’s overall survival, but can also decrease the
quality of life due to non-specific side effects associated with the
high toxicity profile of many chemotherapy treatments (Early
Breast Cancer Trialists’ Collaborative Group, 2005; Riihimäki
et al., 2012).
Pegylated liposomal doxorubicin (Doxil, Caelyx, or Lipodox)
was introduced as the first FDA-approved nanomedicine
composed of the commonly used anticancer drug doxorubicin
encapsulated within the core of liposomes. Liposomal
doxorubicin is the first nanomedicine approved for use in
the clinic for a variety of cancer types. It showed significant
improvements in circulation and bioavailability, and leads
to overall reduction of tumor volume while significantly
increasing the long-term survival of patients (Gabizon et al.,
2003). Nanomedicines provide an increase in therapeutic
activity by passively targeting their therapeutic payloads and
using the leaky vasculature commonly associated with many
tumors, a pathophysiological phenotype known as the enhanced
permeability and retention (EPR) effect (Fang et al., 2011). It
has been suggested extensively from pre-clinical models that
active targeting of nanomedicines can provide an additional
improvement in the therapeutic activity compared to solely
relying on the EPR effect and other passive targeting strategies.
Active targeting commonly involves attachment of a homing
molecule onto either the therapeutic drug molecule, such as a
doxorubicin-conjugate (Florent and Monneret, 2008) or onto
a drug delivery system, such as doxorubicin-loaded liposomes
(Shroff and Kokkoli, 2012; Petrenko and Jayanna, 2014). The
homing molecule would then provide cell-specific accumulation
of the therapeutic molecule specifically to the desired cells,
thereby reducing major side effects and also reducing dose-
limiting toxicities commonly seen with highly active molecules
like doxorubicin.
Two broad mechanisms are commonly used to conjugate a
targeting ligand into a liposomal drug delivery system: “pre-
insertion” modifications and post-insertion modifications. “Pre-
insertion” modifications consist of a covalent conjugation of the
targeting ligand to one of the subcomponents of the drug delivery
system before assembly of the nanoparticle. Attachment of a
peptide/protein is commonly achieved by covalent modification
of an activated lipid or polyethylene glycol (PEG)-lipid through
either an amide conjugation or a disulfide/thioether conjugation
(Wang et al., 2012). Following conjugation, the protein-lipid
conjugates can then be used as one of the many assembly
blocks used in a self-assembly mechanism to produce larger
drug delivery systems, such as observed with liposomes (Lee
et al., 2014). There are several advantages of attaching a
ligand prior to nanoparticle assembly including: (1) highly
controlled reaction conditions of ligand to a specific lipid, (2)
more commonly available characterization methods available
for quality control, and (3) a highly stable conjugation of
the ligand to the lipid molecule. However, “pre-insertion”
modifications often require a trained chemist to optimize
reaction conditions/analyze products, result in moderate yields
of the desired final product which then require purification, and
can also degrade the functional activity of the targeting molecule
depending on reaction conditions. Alternatively, post-insertion
methods of nanomedicine modification involve attachment of
a targeting ligand after assembly and drug loading. It has
been reported that some liposomal nanomedicines are stable
enough to perform an amide conjugation to an activated
lipid exposed from the nanomedicine surface, however this
still requires purification of final product before testing (Kung
and Redemann, 1986). Another common method of post-
insertion modification includes the use of a biotinylated lipid
embedded in a lipid bilayer, which will then react almost
irreversibly with a streptavidin-peptide conjugate or streptavidin-
biotin-peptide conjugate (Loughrey et al., 1987). Another
method of post-insertion modification includes the use of pVIII
major coat proteins isolated from filamentous bacteriophage,
such as M13 or fd, that display a targeting motif fused
at the N-terminus of the protein (Petrenko and Jayanna,
2014). Post-insertion methods offer several advantages including
rapid/simple modification reactions, milder reaction conditions
that keep nanomedicines and ligands functionally intact, and
stable non-covalent interactions between nanomedicines and
the attached ligands. However, post-insertion methods can also
cause nanomedicine instability or drug loss during modification
that requires the optimization of reaction conditions to prevent
undesired effects.
Filamentous bacteriophage of class Ff, including phage vectors
such as M13, fd, and f1, are long cylindrical virions (∼1µm ×
6.5 nm) structurally composed of a single-stranded DNA genome
(<10 kbp) and 5 structural proteins (pIII, pVI, pVII, pVIII,
and pIX) (Marvin et al., 2014). Each of the wild-type phage
particles consist of 2700 copies of the pVIII major coat protein,
which accounts for ∼90% of the mass of each virion. The
remaining 10% is derived from the phage’s DNA genome and
also a minor contribution from the four remaining structural
proteins (<1%). Landscape phage display libraries of type f8,
introduce a random peptide fusion into each of ∼4000 domains
of the pVIII major coat protein of the fd-tet vector to create a
unique landscape across the surface of each phage clone (Smith,
1993; Petrenko et al., 1996; Kuzmicheva et al., 2009). Landscape
phage libraries have been used extensively to generate ligands
with specificity toward various cancer phenotypes (Jayanna et al.,
2010a; Fagbohun et al., 2012; Bedi et al., 2014). The pVIII major
coat proteins produced from these phage vectors have an 8- or
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9-mer peptide fusion at the N-terminus and also contain an
intrinsic membrane-spanning domain between residues 21–39
of the wild-type vector. This highly hydrophobic core serves
to accumulate the pre-coat protein in the bacterial membrane
during phage morphogenesis and also participates in formation
of a highly stable phage particle to protect the genome from
degradation. Filamentous phage particles and their isolated
proteins show superior thermal stability while also maintaining
the desired binding capacity compared to antibodies and also
retain functional activity after exposure to harsh environments
including relatively high temperatures (Brigati and Petrenko,
2005) acidic or alkaline solutions, moderate percentages of
organic solvents (Olofsson et al., 1998) and protealytic enzyme
treatment (Schwind et al., 1992) making filamentous phage and
their pVIII major coat proteins ideal candidates for substitute
antibodies in the targeted drug development (Petrenko and
Smith, 2000; Petrenko, 2008). The intrinsic membrane domain
of the pVIII major coat protein has provided an ideal platform
to develop targeted nanomedicines by isolating the major coat
protein and introducing the solubilized proteins into preformed,
drug-loaded liposomes through spontaneous interactions of the
hydrophobic core with the liposome bilayer (Jayanna et al.,
2010b; Wang et al., 2010a; Petrenko and Jayanna, 2014). Several
methods for solubilization and isolation of phage major coat
protein have been studied including phenol extraction, several
classes of detergents and a number of organic solvents. However,
two critical factors that significantly effect the functional activity
of the isolated protein include: (1) rapid aggregation rates
of the protein due to the highly hydrophobic nature of
the protein, and (2) an irreversible conformation change in
secondary structure from α-helical to a β-sheet (Spruijt et al.,
1989; Li et al., 2007; Siegel et al., 2015). Identification of a
solvation procedure that allows high recovery of phage major
coat protein in an α-helical conformation that would also
limit damage to the membrane of pre-formed liposomes is
ideal.
One of the major limitations in ligand screening of
targeted nanomedicines is due to highly complex reactions
and optimizations required to prepare and purify a single
targeted nanomedicine. In this study, we have developed a rapid
protein isolation method to solubilize the pVIII major coat
protein in high concentration, yield, and purity that also retains
the desired functional activity. We show this isolated protein
is then suitable to prepare targeted nanomedicines following
a post-insertion modification strategy of preformed, drug-
loaded liposomes (Figure 1). We hypothesized that optimization
of ligand solubilization and insertion strategies would allow
identification of cancer cell-specific ligands that increase the
desired specific cytotoxic effect of liposomal nanomedicines in
much higher throughput. We demonstrate the application of
this technique for identifying ligands in a single combinatorial
experiment combining novel cancer cell-specific ligands with
a preformed liposomal doxorubicin core to generating 12
nanomedicines targeted with structurally unique ligands and
subsequently screening for their anticancer activity in vitro.
From this screening experiment, we were able to identify
8 novel targeting ligands able to significantly increase the
FIGURE 1 | Phage fusion protein-targeted nanoparticles. Target-specific
phage fusion protein selected from phage libraries can be introduced into
drug-loaded PEGylated liposomes exploiting their intrinsic properties to
spontaneously integrate into lipid bilayers.
therapeutic response of untargeted liposomal doxorubicin across
two different cancer types.
Materials and Methods
Reagents
Reagent grade or higher calcium chloride, chloroform,
hydrochloric acid (HCl), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), phenylmethylsulfonyl
fluoride (PMSF), 2-propanol, proteinase K, and sodium
dodecyl sulfate (SDS) were obtained from Sigma Aldrich
(St. Louis, MO). Lipodox (PEGylated liposomal doxorubicin,
composed of 1,2-distearoyl-sn-glycero-3-phosphocholine,
cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[amino(polyethylene glycol)-2000] (ammonium salt) (DSPE-
PEG2000) in molar ratio 56: 39: 5 containing ∼2mg/mL
encapsulated doxorubicin) was obtained from SUN
Pharmaceutical Ind. Ltd. (Gujaat, India).
Cell Culture
An established breast adenocarcinoma cell line, MCF-7 (ATCC,
HTB-22™), and an established pancreatic adenocarcinoma
cells line, PANC-1 (ATCC, CRL-1469™), were used throughout
this study. All cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA) as a frozen
vial and maintained as described in the technical bulletins
in a 37◦C cell culture incubator with 5% CO2. Cells were
maintained in the recommended basal medium supplemented
with 10% defined fetal bovine serum (FBS) and 1% v/v
100X antibiotics/antimycotics (Ab/Am). Cells were tested for
mycoplasma contamination using a commercial mycoplasma
PCR detection kit (ATCC) and confirmed to be free of
mycoplasma contamination following all experimental
procedures. Eagle’s Minimum Essential Medium (EMEM)
and Dulbecco’s Modified Eagle’s Medium (DMEM) were
obtained from ATCC. Hyclone defined FBS and Gibco 100X
Ab/Am, a cocktail of 10,000U/mL penicillin, 10,000µg/mL
streptomycin, and 25µg/mL amphotericin B, were obtained
from Thermo Fisher Scientific (Waltham, MA).
Frontiers in Microbiology | www.frontiersin.org 3 June 2015 | Volume 6 | Article 628
Gillespie et al. Phage-targeted cancer nanomedicines
Phage Propagation and Protein Isolation in
2-propanol
All general phage handling, propagation, purification, titering,
and DNA sequencing procedures have been described previously
(Brigati et al., 2008; DeSantis et al., 2014). Phage clones
isolated from landscape phage display libraries f8/8 and f8/9
were designated by the sequences of the foreign fusion
peptides. Phage clones DMPGTVLP or VPTDTDYS were
isolated from an in vitro biopanning of the f8/8 library
over MCF-7 breast cancer cells; similarly, the phage clone
VEEGGYIAA was isolated from an in vitro biopanning of
the f8/9 library over MCF-7 breast cancer cells as described
previously (Early Breast Cancer Trialists’ Collaborative Group,
2005; Fagbohun et al., 2012; Riihimäki et al., 2012). Phage clones
ANDVYLD, ANGRPSMT, GLNGRGDPD, or VNGRAEAP were
isolated from the f8/8 library through in vitro biopanning
with Calu-3 non-small cell lung cancer (NSCLC) cells, and
phages DGQYLGSQ, DVRGDGLQ, EPSQSWSM, ETYNQPYL,
or GSSEQLYL were isolated from the f8/8 library by in vitro
biopanning with the PANC-1 pancreatic cancer cells, as
described previously (Gabizon et al., 2003; Bedi et al.,
2014).
Approximately 3 × 1013 phage particles dissolved in 1X
TBS were transferred to a sterile 1.7mL microcentrifuge tube
followed by addition of 3 volumes of 100% 2-propanol and
30µL of chloroform. Phage samples were vortexed vigorously
to mix and shear intact phage particles into its primary
components. Phage DNA was removed from the mixture by
centrifuging at 13,000 × g for 5min at room temperature.
The upper phase containing phage protein was transferred to
a new sterile 1.7mL microcentrifuge tube and stored at 4◦C.
Phage protein concentration was determined by measuring the
UV/Vis absorbance of the solution at 280 nm with a NanoDrop.
Absorbance values were converted to protein concentration, in
mg/mL, using the appropriate 1 A(280) conversion factor as
listed in Table 1.
Characterization of Isolated Phage Protein by
SDS-PAGE
Two-fold serial dilutions of isolated phage protein in 1X
Laemmli sample buffer were heated at 95◦C for 1 h. A 10-
fold dilution of the Precision Plus Protein WesternC Standards
(Bio-Rad, Hercules, CA) was diluted in 1X Laemmli sample
buffer and heated at 95◦C for 10min. Prepared samples were
separated on a 4–20% Mini-PROTEAN TGX polyacrylamide
gel (Bio-Rad, Hercules, CA) at a constant voltage of 100V
for 45min. Following separation, the gel was fixed for
10min in a methanol/acetic acid/water (v/v/v 50:10:40) fixing
solution. Protein bands were labeled with a Colloidal Blue
Staining Kit (Thermo Fisher Scientific, Waltham, MA) as
described in the manufacturer’s instructions. Briefly, the fixed
gel was incubated in the prepared staining solution (stainer
A/stainer B/methanol/water v/v/v/v 20:5:20:55) for 3 h at room
temperature with gentle shaking. The staining solution was
replaced with distilled water and destained for 11 h at room
temperature with gentle shaking. Following destaining, bands
were visualized using an EDAS Imaging Station (Eastman Kodak
TABLE 1 | Phage major coat protein (pVIII) properties.
Phage MW (g/mol) 1 A(280) = X mg/mL
ANDVYLD 5612.49 0.59
ANGRPSMT 5751.67 0.70
DGQYLGSQ 5786.62 0.58
DMPGTVLP 5747.72 0.70
DVRGDGLQ 5777.65 0.70
EPSQSWSM 5869.76 0.42
ETYNQPYL 5946.84 0.52
GLNGRGDPD 5703.57 0.69
GSSEQLYL 5815.70 0.58
VEEGGYIAA 5711.63 0.60
VNGRAEAP 5731.62 0.69
VPTDTDYS 5815.64 0.61
Phage major coat protein (pVIII) properties were calculated following sequence
analysis of the full length (55 amino acid) pVIII protein sequence using
DNAStar Protean version 10.0.1. Phage are identified by their 8- or 9-mer
fusion peptide sequence within the full length protein sequence of NH2-
AXXXXXXXX[D/X]PAKAAFDSLQASATEYIGYAWAMVVVIVGATIGIKLFKKFTSKAS-COOH,
where X can be any amino acid. Proteins with an 8-mer peptide fusion will contain a D
in the 10th position of the pVIII fusion protein, while proteins with a 9-mer peptide fusion
will have a random amino acid.
Co., Rochester, NY) equipped with a DC290 digital camera
and a white light box. Images were captured and analyzed
using Molecular Imaging Software (v. 4.0.3; Eastman Kodak Co.,
Rochester, NY).
Preparation and Characterization of Phage
Protein-modified Liposomal Doxorubicin
Insertion of Phage Protein into Liposomal
Doxorubicin (Lipodox)
Phage protein-modified Lipodox was prepared at room
temperature (20◦C) by rapidly introducing isolated DMPGTVLP
major coat protein into a preparation of Lipodox at a protein-
to-lipid weight ratio of 1:200 as described previously (Fang et al.,
2011; Wang et al., 2011). Briefly, isolated phage protein (2µL)
was added to 45µL aliquots of Lipodox (90µg doxorubicin)
and mixed vigorously before addition of 1 volume of 1X
TBS, pH 7.4 to the sample. Samples were incubated at
37◦C overnight with gentle rotation. For screening assays,
buffer was exchanged to dilute any residual 2-propanol by
washing the liposomes in a 100K NanoSep centrifugal filter
device (Pall Co., Port Washington, NY) with 5 volumes
of 1X PBS, pH 7.2 for 5min. Samples were centrifuged at
14,000 × g for 10min and the flow through was removed.
Liposomes were recovered from the retentate and analyzed as
below.
Theoretical Calculation of Ligands per Liposome
The number of lipids per liposomes was calculated based on the
surface area of a unilamellar liposome with a bilayer thickness, h,
of 5 nm; an average diameter, d, of 83 nm; and an average lipid
headgroup area, a, of 0.5775 nm2 for the mixed lipid population
according to previous reports (Pidgeon and Hunt, 1981) as
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discussed briefly below:
NLipids =
4pi
a
[(
d
2
)2
+
(
d
2
− h
)2]
The concentration of liposomes was subsequently calculated as
follows, where the molar concentration of lipid in Lipodox, M,
was 0.0216 M; and NA is Avagadro’s Number:
CLipos
(
Liposomes/mL
)
=
M × NA
NLipids × 1000
The number of ligands per liposome was calculated as follows,
where Nligand is the number of phage proteins calculated from
the molar mass:
NLigands/Liposome =
NLigands
NLiposomes
.
Purification of Phage Protein-modified Lipodox by
Size Exclusion Chromatography
Protein modified Lipodox was purified by size exclusion
chromatography (SEC) on a column (30 × 1 cm) packed with
Superose 6 prep grade resin (GE Healthcare, Little Chalfont, UK)
as described previously (Florent and Monneret, 2008; Jayanna
et al., 2009). Liposomes were eluted with 10mM Tris-HCl, pH
8.0 containing 0.2mM EDTA at a flow rate of 0.25mL/min. The
elution profile was monitored by an Econo UV monitor (Bio-
Rad, Hercules, CA) at an AUFS of 0.5 with fractions collected
every 10min (2.5mL fractions). Fractions were stored at 4◦C
until further analysis.
Quantification of Doxorubicin
Encapsulated doxorubicin was quantified by monitoring the
absorbance at 492 nm following incubation with Triton X-100
(1% v/v final concentration) and comparing to a standard curve
with known doxorubicin concentrations as described previously
(Jayanna et al., 2010b; Shroff and Kokkoli, 2012; Petrenko and
Jayanna, 2014).
Size Distribution and Zeta Potential of Liposomes
Liposome size distribution was determined using dynamic light
scattering. Briefly, samples were diluted 100-fold with 1X PBS,
pH 7.4 in a plastic sizing cuvette and analyzed on a ZetaSizer
Nano ZS90 (Malvern Instruments Inc., Worcestershire, UK)
maintained at 25◦C with a scattering angle of 90◦ in triplicate.
All liposome samples were found to be unimodal distributions,
however samples were reanalyzed if multiple populations were
identified. Size distributions are presented as the mean of
triplicate Z-averages (nm)± sample standard deviation.
Liposome zeta potential was determined by particle
electrophoretic mobility as measured using laser Doppler
electrophoresis and phase analysis light scattering. Briefly,
samples were diluted 100-fold in 10mM Tris-HCl, pH 8.0 with
0.2mM EDTA in a plastic sizing cuvette and analyzed on a
ZetaSizer Nano ZS90 with a Zeta Dip cell (Malvern Instruments
Inc., Worcestershire, UK). Samples were maintained at 25◦C
during measurement and performed in triplicate. All recorded
samples were equal in conductivity (± 0.01 of mean). Zeta
potentials are presented as the mean of triplicate zeta potentials
(mV)± sample standard deviation.
SDS-PAGE and Western Blot of Modified Liposomes
Aliquots of each fraction following SEC were diluted with an
equal volume of 2X Laemmli sample buffer and heated at 95◦C
for 1 h. Prepared samples were analyzed using a 4–20% Mini-
PROTEAN TGX polyacrylamide gel at a constant voltage of
100V for 45min. Proteins separated by the SDS-PAGE were then
transferred to a polyvinylidene fluoride (PVDF) membrane and
blocked overnight with 1X protein-free PBS/0.05% Tween 20
blocking buffer. Membranes were probed with a rabbit polyclonal
anti-fd IgG (1:5500 dilution, ∼9µg IgG) described previously
(Smith et al., 1998; Wang et al., 2012) incubated with a biotin-SP-
conjugated Affinipure goat anti-rabbit secondary IgG (1:30,000
dilution, ∼1.3µg IgG; Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA Cat # 111-065-003 RRID: AB_2337959)
and with NeutraAvadin-Horseradish Peroxidase (HRP) (1:30,000
dilution) and visualized with West Pico substrate solution
(Pierce, Rockford, IL). Membranes were imaged on a C-DiGit
blot scanner (LI-COR, Inc., Lincoln, NE) and analyzed by
densitometry with Image Studio Lite (v. 4.0; LI-COR, Inc.).
To ensure the N-terminus was exposed to the exterior
environment of the liposome following phage protein
modification, a proteinase K digestion assay was performed
on modified Lipodox as described previously (Jayanna et al.,
2010b; Lee et al., 2014). Briefly, an aliquot of protein-modified
liposomes were treated with 1.25µg of proteinase K containing
0.25mM CaCl2 for 1 h at room temperature. The reaction was
inhibited by the addition of PMSF to a final concentration 5mM
followed by incubation at room temperature for 5min. Samples
were analyzed by SDS-PAGE and Western blot as described
above.
Phage Protein Orientation Assay of Modified
Liposomes by Dot Blot Analysis
Samples were prepared as described above, except proteinase
K reactions were performed overnight with gentle rotation at
37◦C. Samples were then diluted 2-fold with distilled water and
1.0µL of each sample were dotted onto a 0.2µm nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA). Dots were
allowed to dry overnight at room temperature. The resulting
dots were probed with rabbit anti-Fd IgGs with specificity
toward either the pVIII N-terminus (1:5000 dilution, ∼9.24µg
rabbit anti-Fd IgG) or C-terminus (1:100 dilution, ∼126µg
rabbit anti-Fd C-terminus IgG affinity purified). Membranes
were then treated as above with a biotinylated-SP-conjugated
goat anti-rabbit secondary IgG, NeutraAvadin-HRP and West
Pico substrate before imaging with a C-DiGit blot scanner and
quantified using Image Studio Lite.
Concentration of Modified Liposomes
Liposomes were concentrated by Amicon 100 k Molecular
Weight Cut Off (MWCO) centrifugal concentration devices
(EMD Millipore, Billerica, MA) as follows. Briefly, a 100 k
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MWCO concentrator was washed with 2mL of 10mM Tris-
HCl, pH 8.0/0.2mMEDTA running buffer. Samples were applied
and centrifuged at 5000 × g in 15min increments at 4◦C until
all samples were concentrated to a final volume of 0.5mL.
Doxorubicin liposomes found in the retentate were recovered
and analyzed as above.
Characterization of Liposome Modification by
Flow Cytometry
Phage displaying the fusion peptide DMPGTVLPwas propagated
as above, however phage was dissolved in 1X PBS, pH 7.2
at the final recovery step. Phage proteins were labeled with
an Alexa 488 Protein Labeling kit (Invitrogen, Waltham,
MA) as described previously (Kung and Redemann, 1986;
Fagbohun et al., 2012) and according to the manufacturer’s
instructions. Briefly, phage were added to a vial of reactive dye
at room temperature and mixed for 1 h at room temperature.
Unreacted dye was inactivated by addition of 1X TBS, 7.4
and removed by an overnight PEG precipitation of phage and
solubilization in 1X TBS, pH 7.4. Phage protein was isolated in
2-propanol as described above and the degree of protein labeling
was determined according to the manufacturer’s instructions.
Lipodox was modified with labeled protein as described above.
Liposomes were analyzed on an Accuri C6 flow cytometer (BD
Biosciences, Franklin Lakes, NJ) with an excitation wavelength
of 488 nm and emission collected on three different channels
(533/30, 585/40, and 670LP). The collection threshold was set to
collect events greater than 10,000 on the forward scatter height
(FSC-H) channel. After collection, a threshold to collect events
greater than 1000 RFU on the 670LP height (FL3-H) channel
was applied to reduce the background noise. A minimum of
100,000 events was collected per sample for analysis. Channels
were compensated for channel spillover using single labeled
controls. Labeled phage protein was monitored with the 533 nm
emission filter channel and Lipodox was monitored on both
585 and 670 nm emission filter channels. Flow cytometry data
were captured and analyzed using the Accuri C6 Software
(ver. 1.0.264.21; BD Biosciences). All flow cytometry data files
were annotated and deposited into the publically available
flow cytometry data repository FlowRepository (Repository
ID: FR-FCM-ZZJY) (Loughrey et al., 1987; Spidlen et al.,
2012).
Cell Viability of Cancer Cells Treated with Phage
Protein-modified Liposomes
Cell viability was determined by MTT assay as described
previously (Bedi et al., 2014; Petrenko and Jayanna, 2014).
Briefly, MCF-7 breast cancer cells were seeded at an initial
density of 5 × 105 cells per well in a 96-well cell culture-treated
array plate and incubated at 37◦C for 24 h. Lipodox samples
(modified and unmodified) were diluted in EMEM containing
10% FBS and added to the cells for 24 h. For the screening
assay, medium containing Lipodox was removed from the cells
and replaced with an equal volume of fresh culture medium
containing 10% FBS and incubated at 37◦C for an additional 48 h
before measuring viability. Following treatment, the medium
was replaced with phenol red-free MEM containing 0.45mg/mL
MTT and incubated for 4 h at 37◦C. After 4 h, 100µL of 10%
SDS in 0.01 N HCl was added to each of the wells and incubated
at 37◦C for an additional 4 h. The absorbance of the wells was
measured at 570 nm using a Synergy H1 plate reader (BioTek,
Winooski, VT). Blank wells containing only culture medium and
MTT were subtracted from each sample. The percent viability
was expressed as a ratio between the absorbance of treated cells
by the average absorbance for a set of untreated cells.
Quantification of Cell-associated Doxorubicin
Cell-associated doxorubicin was quantified as previously
described (Bedi et al., 2014; Marvin et al., 2014) with minor
modifications. Briefly, cells were plated at 5000 cells per well in
a 96-well culture plate and incubated overnight in a 5% CO2
cell culture incubator at 37◦C. Cells were then treated with
2µg of doxorubicin of either (1) unmodified Lipodox or (2)
DMPGTVLP-Lipodox for 4 different time periods (4, 8, 12,
and 24 h). Cells were washed twice with 1X PBS, pH 7.2 before
extracting cell-associated doxorubicin with 0.075 N HCl in 90%
2-propanol and incubating at 4◦C overnight. Doxorubicin was
determined by measuring the fluorescence (470 ex/590 em)
with a Synergy H1 plate reader (BioTek, Winooski, VT) using
untreated cells as a blank.
Statistics
Data from all experiments are expressed as the mean ±
sample standard deviation (SD). Differences between samples
were determined using the Student’s independent t-test or and
alternative appropriately identified test listed in the text with a
P < 0.05 as being statistically significant.
Results
Isolation of pVIII Major Coat Protein in 2-propanol
To prepare solubilized phage major coat protein in 2-propanol,
we added 3 volumes of 2-propanol to ∼ 2.3 × 1013 virions
of intact DMPGTVLP phage particles, which displays the full
length, 55 amino acid pVIII major coat protein sequence of NH2-
ADMPGTVLPDPAKAAFDSLQASATEYIGYAWAMVVVIVG
ATIGIKLFKKFTSKAS-COOH (designated shortly by the
sequence of peptide fusion at the N-terminus; DMPGTVLP)
and a small volume of chloroform to perturb the hydrophobic
interactions between neighboring pVIII monomers (Manning
et al., 1981; Smith, 1993; Petrenko et al., 1996; Kuzmicheva et al.,
2009). After exposing intact phage to increased shear force by
vortexing, phage ssDNA was released from the phage particles
and precipitated in 75% 2-propanol. UV/Vis spectroscopy
of the phage protein supernatant (Figure 2A) revealed a
spectrum commonly observed for a pure protein sample with
a corresponding 260/280 ratio of 0.559, which is close to the
theoretical 260/280 ratio of 0.5 expected for pure pVIII major
coat protein. Conversion of A280 into a corresponding mass
revealed a quantitative recovery of the protein mass (∼1mg).
To test the purity of isolated phage major coat protein,
serially diluted samples of phage protein were separated on a 4–
20% polyacrylamide gel and stained with a colloidal Coomassie
blue staining solution. The stained protein gel (Figure 2B)
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FIGURE 2 | (A) UV/Vis spectrum (1 nm scan) of pVIII major coat protein
solubilized in 75% v/v 2-propanol/1X TBS, pH 7.4 blanked with solution of 75%
v/v 2-propanol/1X TBS, pH 7.4. (B) SDS-PAGE of pVIII major coat protein
solubilized in 75% 2-propanol/1X TBS, pH 7.4 separated on a 4–20%
polyacrylamide gel. Bands were identified by staining with a colloidal blue
staining kit (Invitrogen) to reveal a single, low molecular weight band of∼7.5 kDa
(as noted by the arrow) in samples 1 and 2.M (Marker)—1:10 dilution of
Precision Plus Protein WesternC Standards (Bio-Rad), Sample 1–1.36µg
DMPGTVLP phage protein, Sample 2–0.27µg DMPGTVLP phage protein.
reveals a single, low molecular weight protein band at an
apparent molecular weight of ∼7.5 kDa, which corresponds to
the monomeric-form of phage major coat protein (calculated
molecular weight of 5.75 kDa, DNAStar Protean v. 10.0.1). Major
coat protein, pVIII, was detectible down to ∼200 ng of protein
under these conditions with colloidal blue staining.
Preparation and Physicochemical
Characterization of Phage Protein-modified
Liposomal Doxorubicin
To prepare targeted Lipodox (pegylated liposomal doxorubicin,
2 mg/mL doxorubicin) preparations, 23.6µg of isolated
DMPGTVLP phage major coat protein was rapidly added
to liposomes, composed of 4.73mg of lipid and 0.9mg of
doxorubicin, in small aliquots to prevent dissolution of the
liposomes. The residual 2-propanol and chloroform were diluted
to a final concentration of 2.0 and 0.076% respectively, was shown
previously to not cause an increased dissolution of liposomes
(data not shown). Following incubation at 37◦C overnight,
samples were eluted through a size exclusion chromatography
column packed with Superose 6 and the elution profile was
monitored by relative absorbance with a UV/Vis monitor. The
elution profile for DMPGTVLP-modified Lipodox (Figure 3)
showed a single broad peak with 2minor peaks at either side of
the main peak (fractions 4 and 9). The broad peaks observed
were also present in unmodified liposomes and is hypothesized
to be due to the heterogeneous composition of the liposomes,
however both minor peaks were excluded from further analysis.
To ensure phage protein was associated with the liposomes,
a Western blot of each fraction (fractions 5–11) was performed
with an anti-fd phage IgG that demonstrates specificity toward
the N-terminus of the major coat protein. The blot revealed a
single ∼5.7 kDa molecular weight band with most of the phage
protein associated with the liposomes found in fractions 6 and
7, however phage protein was also recovered in fractions 5–10
(Figure 3). Phage protein was not observed as free protein in
the absence of liposomes. Fractions 5 through 8 were further
characterized for recovery of doxorubicin and physical properties
(size distribution and zeta potential) of the recovered liposomes.
As shown in the summary table (Figure 3), 862µg of doxorubicin
(95.79% yield, 900µg doxorubicin input) was recovered in
the 4 fractions, which was significantly higher than previous
post-insertion methods using cholate, which commonly resulted
in 50–80% doxorubicin recovery. The size distribution of the
resulting fractions showed a mean diameter of 81.25 ± 3.36 nm
with an average PDI of 0.127 ± 0.029, which corresponds to
a monodisperse population of liposomes with a low tendency
for particle aggregation. The zeta potential of the fractions
showed a mean zeta potential of −30.25± 10.0mV with a mean
conductivity of 0.020 ± 0.005mS/cm, which suggests a generally
negative surface charge of the liposomes in a solution of constant
ionic strength and composition.
Since fractions 5 through 8 displayed similar composition
and physical properties, they were concentrated with 100K
MWCO centrifugal concentration devices and analyzed again
for final characterization properties. After concentration, 589µg
of doxorubicin (68.4% recovery, 862µg doxorubicin input) was
recovered; suggesting a large portion of doxorubicin was lost
during concentration most likely due to doxorubicin sticking
or passing through the membrane. Following concentration,
DMPGTVLP-modified liposomes showed a mean diameter of
80.27 ± 1.30 with an average PDI of 0.104 ± 0.015, which shows
no statistically significant change in size or aggregation due to
concentration effects (two-tailed t-test, P = 0.605 and P =
0.196 respectively). DMPGTVLP-modified liposomes showed
a significant 11.3% increase in size compared to unmodified
Lipodox (72.07 nm; two-tailed t-test, P = 8.06× 10−3), however
this increase is negligible in the biological systems to be tested
and is hypothesized to be due to swelling associated with major
coat protein incorporation. After concentration, DMPGTVLP-
modified liposomes showed a mean zeta potential of −19.87 ±
0.50, which again shows no statistically significant difference
in zeta potential due to concentration effects (two-tailed t-test,
P = 0.08). Modified liposomes showed a significant 11.4%
decrease in zeta potential compared to unmodified Lipodox
(−17.83mV; two-tailed t-test, P = 4.2× 10−2). We hypothesize
that observed decrease might be due to the introduction of the
fusion pVIII major coat protein, which contains a negatively
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FIGURE 3 | Purification and characterization of DMPGTVLP-modified
Lipodox. Size exclusion chromatography of modified Lipodox on a Superose
6 column (30× 1 cm), 2.5mL/fractions 4–11 of the elution profile are shown.
Western blot of recovered fractions probed with a polyclonal anti-fd rabbit
primary IgG, followed by a biotinylated goat anti-rabbit secondary IgG and
detected with NeutrAvadin-HRP and Pico West luminol substrate.
Physicochemical characterization of recovered fractions for size distribution
(d.nm), zeta potential (mV), doxorubicin recovery (µg), and percent doxorubicin
recovery (%).
chargedN-terminus that is exposed to the environment following
liposome modification and can influence the observed charge at
the liposome surface.
We next sought to determine if the N-terminus of the
fusion protein, which contains the cancer cell-specific targeting
domain, was exposed outside of the liposomal environment
following concentration as previously shown (Jayanna et al.,
2010a,b; Fagbohun et al., 2012; Bedi et al., 2014). As illustrated
in Figure 4A, treatment of modified liposomes with proteinase
K causes protein not protected by the liposome membrane
to be hydrolyzed. To show that the N-terminus is exposed, a
portion of modified liposomes was treated with proteinase K
followed by SDS-PAGE and detection of the N-terminus of major
coat protein with an anti-fd antibody. The resulting blot and
densitometry of bands shows that isolated major coat protein can
be detected as a single 5.7 kDamolecular weight band at the same
protein mass used in a matched liposome modification (∼500 ng
of protein analyzed) and subsequently degraded to completion
when treated with proteinase K under these conditions as
expected (Figure 4B, lanes 1 and 2 respectively). After insertion
into Lipodox, phage protein is detected in untreated samples and
is absent following treatment with proteinase K (Figure 4B, lanes
3 and 4 respectively), suggesting that the N-terminus is exposed
following modification and liposome concentration as expected.
As previously suggested, we hypothesized that the C-terminus
of the phage major coat protein would be embedded in the
hydrophobic membrane and protected from degradation by
proteases. We therefore sought to determine the orientation of
the C-terminus by a semi-quantitative dot blot assay. It was
shown previously that degradation of the N-terminus produces a
highly hydrophobic protein fragment that results in irreversible
aggregation of monomers, causing visible smearing of bands
in Western blots probed with a C-terminus specific antibody.
To overcome this limitation and produce semi-quantitative
estimates of the amount of each terminus following degradation,
we optimized a dot blot assay and probed the resulting
membranes with anti-fd IgGs with specificity to either the N- or
C-terminus of the major coat protein (Figure 4C). Treatment of
a 1X phage protein sample (∼375 ng) with proteinase K resulted
in complete degradation of the protein and was undetectable
with both N- and C-terminal antibodies. To ensure reaction
conditions were optimal for excess phage protein, a 2X phage
protein sample (∼750 ng) was digested under the same reaction
conditions to again reveal complete degradation of the both N-
terminus and C-terminus of the phage protein.Modified Lipodox
(containing 375 ng phage protein) was digested with proteinase K
using the same reaction conditions and probed with N-terminal
and C-terminal specific antibodies. Probing the proteinase K
treated Lipodox sample with the N-terminal antibody revealed
complete degradation, confirming previously observed results
obtained by Western blot (Figure 4B). Similarly, probing the
same proteinase K treated Lipodox sample with a C-terminal
specific antibody revealed no degradation of protein.
Estimation of the Degree of Protein Modification
by Flow Cytometry
We further sought to determine an approximate degree of
liposome modification by monitoring individual liposomes with
flow cytometry. To estimate the modification efficiency of
modified liposome, we fluorescently labeled intact phage particles
with Alexa Fluor-488 and isolated the labeled protein as above.
We have shown previously that intact phage can be modified
with an amine-reactive Alexa Fluor-488 N-hydroxysuccinimide
(NHS)-ester that reacts with the N-terminal amine and the
exposed ε-amine of Lys-13 on pVIII major coat protein (Brigati
and Petrenko, 2005; Fagbohun et al., 2012). The resulting degree
of fluorescence labeling was calculated to be ∼10% of the total
phage protein mass, which is routinely achieved for phage after
amine modification. Following isolation of pVIII protein, 25µL
of Lipodox (50µg of doxorubicin) was modified with 14.4µg of
protein in which 10% of protein (1.4µg) was labeled with Alexa
Fluor-488.
We hypothesized that these particles could then be quantified
by flow cytometry with individual particles containing
doxorubicin being identified by a relative fluorescence
threshold of 1000 RFU set on the 670LP emission filter to
reduce background noise. Unmodified Lipodox liposomes were
analyzed across two channels (Em 585/40 and 670LP filters) to
accurately identify liposomes from random background events.
The Lipodox positive gates were identified on each channel from
the samples displaying a linear correlation across both channels,
identifying 95.6% of the sample population. Due to the broad
emission spectrum of doxorubicin, the fluorescently labeled
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FIGURE 4 | (A) Schematic of phage protein orientation assay, where it is
expected that the N-terminus of the protein is exposed to proteinase K
degradation while the C-terminus of the protein is protected from degradation
by the lipid bilayer. (B) N-terminal orientation assay in DMPGTVLP-modified
Lipodox. SDS-PAGE of concentrated DMPGTVLP-modified Lipodox followed
by assay by Western Blot. M (Marker)—1:10 dilution of Precision Plus
WesternC Standards, Samples 1 and 2–500 ng DMPGTVLP isolated protein,
Samples 3 and 4—DMPGTVLP-modified Lipodox (∼500 ng DMPGTVLP
protein). Samples 1 and 3—untreated controls, Samples 2 and
4—Proteinase K (PK) treated samples. (C) Phage protein orientation assay
by dot blot analysis with data quantified by densitometry and presented as
the mean ± standard deviation of output signal normalized to 1X untreated
protein (∼375 ng protein). Untreated samples (dark bars) are compared to
proteinase K treated samples (light bars) N = 3.
protein positive gate was identified at the maximum emission
fluorescence of unmodified Lipodox using a 533/30-emission
filter. The resulting gate also identified free-protein aggregates
displaying high particle fluorescence. Analysis of unmodified
Lipodox shows that 96.5% of the total population is found in
the doxorubicin positive/protein negative quadrant (lower-
right) with a minimal percentage in the doxorubicin/protein
positive quadrant (upper-right) (Figure 5A). After liposome
modification, there was a significant increase to 6.5% of the total
population found in the doxorubicin/protein positive quadrant
(upper-right) and a significant increase to 4.5% of the total
population found in the doxorubicin negative/protein positive
quadrant (upper-left) (Figure 5B). Since free protein was found
to have high channel fluorescence, we suggest that the observed
increase in the doxorubicin negative/protein positive quadrant
(upper-left) is due to minor loss of encapsulated doxorubicin in
modified liposomes below our doxorubicin positive gate. We
therefore show a total detectible protein positive population
of 11%.
Cytotoxicity and Uptake of DMPGTVLP-modified
Lipodox in Breast Cancer Cells
It was shown previously that DMPGTVLP-modified Lipodox,
with modification by cholate solubilized phage protein, would
significantly increase the toxicity in MCF-7 breast cancer
cells in vitro and also in vivo (Olofsson et al., 1998; Wang
et al., 2010a,b, 2014). We therefore sought to determine
FIGURE 5 | Flow cytometry analysis of (A) unmodified Lipodox and (B)
488-labeled-DMPGTVLP-modified Lipodox. Doxorubicin quantified on
670LP emission channel and 488-labeled phage protein quantified on 533/30
emission channel. Samples were excited using a 488 nm laser.
if liposome modification by phage protein solubilized in 2-
propanol would produce similar results. MCF-7 cells were
incubated with DMPGTVLP-modified Lipodox or unmodified
Lipodox dilutions for 24 h before quantification of viable cells
by MTT assay. DMPGTVLP-modified Lipodox produced a
significant decrease in the number of viable cells compared to
unmodified Lipodox samples under the same conditions in a
dose dependent manner at higher doxorubicin concentrations
of 30µg/mL (62.7 ± 2.5 vs. 80.6 ± 3.7% viable; two tailed
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t-test, P = 8.11 × 10−4) and 60µg/mL (32.3 ± 1.3 vs. 50.8
± 2.5% viable; two tailed t-test, P = 4.97 × 10−3) as expected
(Figure 6).
As shown previously, the increased cytotoxicity observed with
DMPGTVLP-modified Lipodox is due to an increased uptake of
targeted Lipodox in target cells compared to untargeted Lipodox.
We therefore hypothesized that there would be a significant
increase in intracellular doxorubicin over time in DMPGTVLP-
modified Lipodox compared to unmodified Lipodox. We show
over a 24-h time period, there is a significant increase in
cell-associated doxorubicin in DMPGTVLP-modified Lipodox
compared to the unmodified control Lipodox (Figure 7). After
12 h of incubation, there is a significant increase in fluorescence
of∼710 RFU (two-tailed t-test, P = 1.82× 10−4) corresponding
to an increase of ∼1.6µg of total doxorubicin compared to
unmodified (328.8 pg of increased doxorubicin/cell). Similarly,
after 24 h of incubation, there is a significant increase in
fluorescence of ∼640 RFU (two-tailed t-test, P = 3.99 ×
10−3) corresponding to an increase of ∼1.5µg of total
doxorubicin compared to unmodified (294.9 pg of increased
doxorubicin/cell). We therefore can confirm that modification of
Lipodox by phage major coat protein in 2-propanol retains the
previously observed increased cytotoxicity of targeted Lipodox
via an increased delivery of doxorubicin to breast cancer
cells.
Screening of Phage Protein-modified Lipodox
We next sought to screen a number of cancer cell-specific phage
proteins isolated in 2-propanol to identify a panel of phage
proteins that may enhance the specific toxicity of Lipodox toward
cancer cells. We hypothesized that screening ligands in this
manner would significantly increase the throughput of ligand
identification for targeted drug delivery using a common Lipodox
platform and varying the targeting ligand while retaining a
FIGURE 6 | MTT viability assay of MCF-7 cells treated with dilutions of
Lipodox (dark bars) or DMPGTVLP-modified Lipodox (light bars) after
24h of incubation. Data are presented as the mean ± sample standard
deviation of the percent viable fraction compared to untreated control cells,
which were taken as 100% viable. N = 3; *P < 0.05, paired, two-tailed
Student’s t-test vs. unmodified Lipodox.
common incorporation method. We initially screened 9 different
ligands in MCF-7 breast cancer cells, which are commonly
sensitive to doxorubicin. Next we screened an additional 5
ligands in PANC-1 pancreatic cancer cells, which are commonly
reported to express a multiple drug resistance (MDR) phenotype
and become resistant to doxorubicin treatment. Phage protein-
modified Lipodox samples were prepared and characterized
as above and summarized in Table 2 to identify preparation
parameters for potential bias in the observed toxicity. As shown
previously, all modified samples demonstrated a significant
increase in mean size distribution (two-tailed t-test, P <
0.05). Five of the prepared samples (ANDVYLD, EPQSQWSM,
VEEGGYIAA, DGQYLGSQ, and DVRGDGLQ) demonstrated a
statistically significant change in zeta potential (two-tailed t-test,
P < 0.05), however they were all within a biologically acceptable
range. On average, most insertions produced high doxorubicin
recovery rates (mean recovery 82.8 ± 20.4%) with no significant
loss of doxorubicin following modification (mean loss 3.34 ±
2.02%). Modification with the protein ligand ANDVYLD caused
significant loss of recovered doxorubicin (33.8%), however there
was still sufficient material to complete the assay and all other
parameters were similar to the other preparations.
Following Lipodox modification and characterization, we
hypothesized that targeting ligands specific for a certain cell
type would increase the toxicity of Lipodox as suggested
previously. MCF-7 breast cancer cells were treated with the 9
different phage protein-modified Lipodox and cell viability was
measured 72 h after initial treatment. As shown in Figure 8A
and from the calculated IC50 values in Table 2, there were a
number of protein-modified Lipodox samples that significantly
increased the toxicity profile of unmodified Lipodox, including
DMPGTVLP as shown previously. The ligands screened stratified
into three different groups covering a 100-fold change in
IC50: (1) ligands showing no improvement from unmodified
FIGURE 7 | Doxorubicin uptake assay in MCF-7 cells treated with 2µg
of Lipodox (dark bars) or 2µg DMPGTVLP-modified Lipodox (light
bars) over 24h. Data are presented as the mean ± sample standard
deviation of the relative fluorescence of doxorubicin at an excitation
wavelength of 470 nm and emission wavelength of 590 nm. N = 3; *P < 0.05,
paired, two-tailed Student’s t-test vs. unmodified Lipodox.
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TABLE 2 | Phage protein-modified Lipodox characterization.
Phage Protein added
(µg)
Recovered
doxorubicin (%)
Free doxorubicin
(%)
Size distribution
(d.nm)
Zeta potential
(mV)
IC50(µg/mL)
ROUND 1—MCF-7 BREAST CANCER CELLS
ANDVYLD 0.41 33.84 1.61 81.75 ± 0.31* −19.9± 0.1* 0.6
ANGRPSMT 0.86 109.02 1.72 80.53 ± 0.62* −18.4± 1.4 0.5
DMPGTVLP 0.60 105.38 6.59 79.50 ± 1.44* −18.3± 0.7 1.3
DVRGDGLQ 1.49 85.19 1.62 82.00 ± 0.66* −19.0± 0.7 30.0
EPSQSWSM 1.24 104.46 2.83 80.47 ± 0.54* −19.7± 0.3* 2.8
GLNGRGDPD 0.53 110.92 2.71 80.39 ± 1.40* −18.7± 0.6 3.2
VEEGGYIAA 0.53 73.91 1.72 81.36 ± 1.28* −21.3± 0.7* 2.6
VNGRAEAP 0.97 59.18 1.42 80.80 ± 1.49* −18.4± 1.3 0.6
VPTDTDYS 1.38 77.99 1.61 80.74 ± 1.30* −18.5± 0.4 3.3
No Protein N/A 98.51 1.18 73.46 ± 0.49 −18.6± 0.4 13.5
ROUND 2—PANC-1 PANCREATIC CANCER CELLS
DGQYLGSQ 1.58 75.75 4.88 89.11 ± 1.70* −16.7± 0.5* NCa
DVRGDGLQ 2.48 81.20 5.91 88.98 ± 0.50* −16.7± 0.5* NCa
EPSQSWSM 0.93 82.34 5.10 89.06 ± 0.91* −17.7± 0.5 NCa
ETYNQPYL 0.50 80.37 6.37 90.72 ± 1.21* −19.7± 0.8 NCa
GSSEQLYL 1.22 79.71 4.80 89.66 ± 1.07* −17.4± 0.5 NCa
aNC, Not calculated; *p < 0.05, paired two-tailed Student’s t-test vs. unmodified Lipodox (control).
Lipodox (Figure 8A, squares), (2) ligands showing moderate
improvement (Figure 8A, diamonds), and (3) ligands showing
large improvements (Figure 8A, circles). As expected ligands
with similar structural motifs grouped together, such as
ANGRPSMT and VNGRAEAP, and produced similar IC50
values. Correlations between all factors in Table 2 compared to
the IC50 were performed to identify parameters that might have
influenced the toxicity profile apart from the targeting ligand
and all parameters had a low to weak Pearson’s R correlation
(R < 0.3) suggesting the observed increase in toxicity were due
to the cell-specific targeting ligands.
PANC-1 pancreatic cancer cells are shown to be resistant
to doxorubicin by a MDR phenotype caused by overexpression
of P-glycoprotein (Pgp) eﬄux pumps that prevent doxorubicin
from accumulating within the cancer cells (Figure 8B, black
square). However, we hypothesized that introduction of a
cell-specific targeting ligand into Lipodox would be able to
overcome the observed drug resistance. We showed previously
that drug resistance could be overcome by addition of the ligand
EPSQSWSM to Lipodox (Schwind et al., 1992; Bedi et al., 2014).
We therefore sought to identify other ligands with specificity
toward pancreatic cancer that would also significantly increase
the toxicity of unmodified Lipodox in PANC-1 pancreatic cancer
cells. Five ligands with specificity toward PANC-1 pancreatic
cancer cells were inserted and screened as above with liposome
characterization parameters identified in Table 2. As shown
in Figure 8B, all ligands significantly increased the toxicity of
unmodified Lipodox at high concentrations (two-tailed t-test,
P < 0.001) and a subset of ligands [DGQYLGSQ, ETYNQPYL,
and GSSEQLYL] showed a statistically significant increase in
toxicity at doxorubicin concentrations of 12 and 24µg/mL as well
(two-tailed t-test, P < 0.05).
Discussion
Although targeted nanomedicine delivery has demonstrated its
efficiency in systemic cancer treatment in animal models and
recently shown success in an ongoing Phase II clinical trial
(Petrenko and Smith, 2000; Petrenko, 2008; Hrkach et al., 2012)
identification of ideal targeting ligands for active tumor targeting
remains a significant challenge. Many methods require multiple
conjugation or purification steps before testing the functional
activity of a ligand in a given nanomedicine scaffold. A number
of these strategies are expensive, time consuming, require large
batch volumes due to reactions that produce products with
a low overall yield, or require modification of an identified
ligand before conjugation. These limitations effectively reduce
the ability to screen large numbers of ligands even within the
same nanomedicine scaffold. Phage display has been commonly
used as a source of novel ligands for various cancer related
diagnostic or therapeutic markers. The most commonly used
phage display libraries are performed with Ff class of filamentous
bacteriophage vectors (including M13, fd, and f1) that displays a
random peptide on the pIII minor coat protein, which supports a
peptide insert of many different sizes (Smith and Petrenko, 1997;
Jayanna et al., 2010b; Wang et al., 2010a; Petrenko and Jayanna,
2014). However, the pIII minor coat protein is only expressed in
5 copies at the infectious head of each phage particle, making
it necessary to synthesize the identified cell-specific ligands
separately from the phage and conjugate it to the nanoparticle
carrier that may compromise the specific binding properties of
the selected peptides. Previously, we have generated another type
of display system—landscape phage in which the N-terminus of
every copy of the pVIII major coat protein is modified with a
randomized peptide fusion of 8 or 9 amino acids and have been
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FIGURE 8 | MTT viability assay of (A) MCF-7 or (B) PANC-1 cells treated
with dilutions of phage protein-modified Lipodox after 24h of drug
incubation followed by 48h of drug washout. Modified samples are
identified by their displayed 8- or 9-mer fusion peptide sequence in the legend
above. Data are presented as the mean ± sample standard deviation of the
percent viable fraction compared to untreated control cells, which were taken
as 100% viable. N = 3; *P < 0.001, paired, two-tailed Student’s t-test vs.
unmodified Lipodox;
#
P < 0.05, paired, two-tailed Student’s t-test vs.
unmodified Lipodox.
used extensively to identify a number of cancer-specific ligands
targeting a number of different cancer phenotypes (Romanov
et al., 2001; Samoylova et al., 2003; Jayanna et al., 2010a;
Fagbohun et al., 2012; Bedi et al., 2014). Since the pVIII major
coat protein is expressed in 4000 copies per phage in these fd-tet-
type vectors (Zacher et al., 1980) scaling of phage propagations up
to 1 L scale can routinely produce protein yields up to 20mg that
can subsequently be purified from the bacteriophage genomic
DNA using a number of standard techniques. Unlike the pIII
minor coat protein, the recovered pVIII major coat protein can
then be used directly in a number of drug delivery systems
via a post-insertion modification of the nanomedicine scaffold
using the inherent peptide domains designed naturally into
the full-length coat protein as shown previously (Petrenko and
Jayanna, 2014). Here we show a novel combinatorial extension
of the phage display technology that allows testing for specific
tumor cytotoxicity in a common nanomedicine core modified
with different phage protein ligands in much higher screening
throughput than traditional technologies to identify candidate
ligands for further optimization.
In this study, we showed that the pVIII major coat protein
could be isolated in 2-propanol to yield highly pure protein
that was free from phage DNA. We hypothesize that the
protein retains the α-helical secondary structure as suggested
by the interaction of protein with liposomes and the solubility
of the isolated protein. Under certain conditions and long
storage conditions, the phage pVIII protein commonly adopts
an irreversible β-sheet conformation, which causes the solubility
of the isolated protein to decrease due to aggregation of large
protein multimers (Spruijt et al., 1989). We do notice that
extended storage of isolated phage protein in 2-propanol at room
temperature will result in precipitated protein aggregates that
remain insoluble in agreement with previous studies showing
freshly prepared samples lose α-helical structure with time.
Thus, freshly prepared phage proteins are recommended for
all applications requiring α-helical protein structure, including
modification of liposomes. The ability to retain the desired α-
helical secondary structure following insertion into drug-loaded
liposomes remains to be studied, however modified liposomes
have been reported to maintain their targeting ability at least a
month after preparation (Wang et al., 2014).
Following a similar insertion scheme as described previously
using sodium cholate to solubilize pVIII proteins, we prepared a
model drug delivery system consisting of isolated DMPGTVLP
protein in 2-propanol inserted into preformed Lipodox
liposomes. We then showed that liposomes were successfully
modified with protein with significantly less loss of doxorubicin
during modification while still retaining functional activity.
As shown from a mock insertion of isolated DMPGTVLP
phage protein into buffer, the complete loss of phage protein
can be suggested to be due to the highly hydrophobic nature
of the pVIII major coat protein causing any free protein to
precipitate or adsorb to other hydrophobic materials. Similarly,
as suggested by the partition coefficient of major coat protein for
POPC (1-palmitoyl-2-oleoyl-sn-glycero-e-phosphocholine) lipid
membranes reported to be 1.0× 105 M−1, it is hypothesized that
100% of the isolated protein will partition into the lipid bilayer
primarily by hydrophobic interactions (Soekarjo et al., 1996).
In an attempt to identify the degree of protein labeling
per liposome, we used semi-quantitative dot blotting and flow
cytometry of intact liposomes to characterize protein-loading
properties following Lipodox modification. From theoretical
calculations based on mass of lipid/liposome and calculated
molecular weights of phage proteins, it is estimated that
there are ∼50–100 ligands per liposome depending on the
diameter of the liposomes used for modification. The data we
obtained from dot blotting suggests there is no free protein
in solution after liposome modification and we maintain a
correct orientation of targeting protein with N-terminus exposed
from the liposome and the C-terminus protected within the
liposome core. Following degradation of phage protein-modified
liposomes with Proteinase K, there was complete degradation of
the N-terminus and no degradation of C-terminus. These data
suggest that Proteinase K is sufficient to degrade all exposed
proteins and 100% of the N-terminus is exposed from the
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liposome surface. We also estimate that 100% of the C-terminus
is protected from degradation suggesting that the insertion of
protein was complete and that no free phage protein is found
in solution. We therefore show that the C-terminus of the pVIII
major coat protein was able to translocate through the liposome
membrane with high orientation specificity. We also show that
following insertion of Alexa 488-labeled DMPGTVLP major
coat protein into Lipodox, there was a significant shift of the
liposome population toward the Alexa 488-positive gate. Only
11% of the liposome population showed a detectible increase in
Alexa 488-positive labeling. Due to the low labeling efficiency
(∼10%) of the phage protein prior to insertion, we are unable
to detect all ligand incorporations into the liposomes and can
only resolve the most fluorescently intense liposomes receiving
large numbers of Alexa 488-labeled phage proteins. Based on an
estimate of 50 ligands/liposome, it can be expected that insertion
of labeled proteins will follow a normal distribution with a mean
of 5 labeled ligands/liposome. However, because of the poor
resolution between the two populations, we can only observe the
(11%) upper-tail of the normally distributed population which
are the most bright. Optimization of fluorophore conjugation
to the phage ligands or changing to a brighter fluorophore
can increase the efficiency of this assay. It was also noted that
there was a slight decrease in the doxorubicin mean channel
fluorescence following modification (unmodified = 7929 RFU
vs. modified = 5679 RFU in 670 LP-H channel) consistent with
a slight loss in encapsulated doxorubicin. Free DMPGTVLP
labeled protein appeared to aggregate heavily and form very
bright particles, however in phage protein-modified Lipodox
we observed only moderate increases in fluorescence. As we
only see moderate increases in fluorescence, this suggests that
there is no detectible free protein in solution with the modified
Lipodox. This data is in agreement with previous reports on
the completeness of insertion using different concentrations of
isolate phage protein while maintaining a constant lipid mass up
to a protein/lipid ratio of 1:200 (Soekarjo et al., 1996; Wang et al.,
2011). We note that a significant limitation of this assay is the
requirement for gating on a fluorescent population of liposomes.
Since we are near the detection limits of the equipment, we
found that empty liposomes, when performed with the same
parameters, produce unreliable results as there is no precise
method to identify liposomes from background noise during
the measurement. We have seen that translocation through
preformed lipid membranes is spontaneous (not requiring any
host proteins), pH and temperature dependent. We propose that
insertion of pVIII major coat protein is a two-stage process:
(1) attachment of protein to the liposome surface, and (2)
translocation of the C-terminus (Figure 9). The association of
isolated pVIII major coat protein has been studied in detail
previously, however the mechanism of C-terminal translocation
has not been fully elucidated. We have previously proposed a
mechanism in which the positively charged C-terminus is able to
penetrate through a lipid bilayer (Petrenko and Jayanna, 2014)
however detailed studies on the mechanism of translocation
remain to be completed.
It remains to be seen whether there is a direct correlation
between the strength of phage ligand binding to a target cell
line and a subsequent increase in functional cytotoxicity activity
in vitro. From our preliminary data, we find that sometimes
weak binding phage clones perform better as targeting ligands
in liposomal nanomedicines than strong binding phages. It has
been suggested that low affinity ligandsmay be ideal for improved
tumor penetration, as actively targeted drug delivery systems
targeted by high affinity ligands are suggested to remain on the
tumor periphery (Gray et al., 2013). For this reason, we used
a functional screening assay of the final targeted nanomedicine
in which new candidate ligands can be identified based on the
desired increase in cytotoxicity rather than building an ideal drug
delivery system based on optimization of individual components.
For the functional screening assays, the drug exposure time
was maintained at 24 h for all viability experiments to prevent
excess drug leakage due to liposome degradation over the total
FIGURE 9 | Spontaneous insertion of the major coat protein into lipid
membranes. (A) In the first step, the isolated coat protein binds to the lipid
membrane using electrostatic interactions of the C-terminus with negatively
charged phosphate headgroups of lipids, followed by the insertion of the
hydrophobic region of the protein into the hydrocarbon core of the lipid
bilayer. (B) In the second step, the hydrophilic tail is released into the trans
side of lipid bilayer through a process similar to cell-penetrating peptides.
From Petrenko and Jayanna (2014).
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measurement time. We have seen minimal doxorubicin leakage
of phage protein-modified doxorubicin liposomes at 37◦C in
the presence of serum over the total test period (data not
shown), however we sought to optimize screening conditions
with alternative encapsulated drugs in mind displaying less
carrier stability. We also increased the total incubation time
of viability assays to a total of 72 h consisting of 24 h with
phage protein-modified Lipodox samples plus an additional 48 h
washout period in complete culture medium. The extended
assay conditions allowed all cells, irrespective of origin, sufficient
time to complete a normal cell cycle and thereby produce an
increased toxicity profile in doxorubicin treated cells due to the
inability of genomic DNA to replicate, resulting in a stalled
cell cycle phenotype in the G0/G1 phase commonly observed
with doxorubicin toxicity (Lukyanova et al., 2009). Given the
broadly defined parameters, this screening assay can therefore
be extended to a variety of cell types and also a number of drug
classes employing different mechanisms of action. A limitation
of this screening assay is the inherent nature of the MTT assay as
a measure of mitochondrial succinate dehydrogenase activity in
metabolically active cells rather than a cytotoxic event. However,
as shown in previous work by us and other authors, doxorubicin
will cause cell death by activation of caspase cascades leading
to apoptosis (Wang et al., 2004). As we have not changed
the properties of the cytotoxic drug and we have shown that
phage proteins are non-toxic (Bedi et al., 2014) we don’t expect
significant changes in the primary mechanism of cell death, only
an increase in intracellular delivery of cytotoxic drug. Since we
have shown previously that the MTT assay is a good indicator of
cell death in this system and death can be confirmed by visual
observations, the reduction in cell viability as determined by the
MTT assay would be sufficient for identification of ligands in a
screening assay.
From our screening experiment in MCF-7 cells, we were
able to identify a previously validated breast cancer cell-specific
protein DMPGTVLP that interacts with cell surface expressed
nucleolin and increases the therapeutic effect of liposomal
doxorubicin in vitro and in vivo by increasing the specific delivery
of doxorubicin to MCF-7 cell nuclei (Wang et al., 2010a, 2014;
Fagbohun et al., 2012). Liposomes modified with a phage fusion
protein displaying the peptide ANDVYLD showed the greatest
increase in toxicity with a calculated IC50 of 0.6µg/mL in MCF-7
cells. We also identified two peptides containing a positionally
constrained NGR motif (ANGRPSMT and VNGRAEAP) that
showed similar toxicity profiles (average IC50 =0.55µg/mL) as
expected. Surprisingly, phage VNGRAEAP did not show binding
to MCF-7 cells in our previous binding assays, however this
limitation may be due to a short binding assay duration (1 h)
compared to the duration of the cytotoxicity assay (24 h) or due to
a difference in primary uptakemechanism between the two phage
as shown previously (Gillespie et al. Submitted). A similar motif
containing a positionally different NGR motif (GLNGRGDPD)
showed improvement in toxicity to 3.2µg/mL, however it was
unable to reach the same toxicity of the other motifs. This may
be due to a difference in the NGR motif availability to the
receptor or an effect of peptide affinity. Inclusion of a pancreatic
cancer-specific ligand (DVRGDLQ) resulted in no significant
increase in toxicity suggesting the specificity of ligands to increase
doxorubicin delivery specifically to the target cells and is not
a result of modification. Screening the DVRGDLQ peptide in
pancreatic cancer cells produced an increase in cytotoxicity
compared to unmodified Lipodox. Interestingly, a subset of
ligands with similar motifs (DGQYLGSQ, ETYNQPYL, and
GSSEQLYL) grouped together to produce similar cytotoxicity
profiles. Comparison of a shared DXXXXGXD motif showed
that there was a significant difference between DVRGDGLQ
and GQYLGSQ ligands at higher concentrations (two-tailed t-
test, P < 0.01) with the DGQYLGSQ ligand producing greater
toxicity suggesting minimal involvement of the DXXXXGXD
motif. Comparison of the YL motif found in different positions
of the three ligands showed no statistical differences between the
three ligands (two-tailed t-test, P > 0.05), however all three
showed significant differences compared to unmodified. These
data therefore suggest the YL motif, irrespective of position,
will cause an increase in toxicity. No putative receptor has been
suggested for any of the three ligands at this time, however it
is interesting to note the number of essential amino acids (Y,
L, W, and V) present in the identified ligands that are typically
underrepresented in our phage display library (Kuzmicheva
et al., 2009). The presented data demonstrate the use of phage
display technology along with a combinatorial screening strategy
to significantly enhance the screening throughput of targeted
nanomedicines that may considerably accelerate progress in
actively targeted drug development.
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